thrives on fermentation services
Using its expertise in
the field of biotechnology and chemistry, Concord is concentrating on
the fermentation-based products.
Gujarat-based Concord Biotech Limited (CBL) clocked annual revenue of
Rs 97.10 crore for 2008-09 as against Rs 60 crore in fiscal 2007-08. It
is an R&D-based biotechnology company having a state-of-the-art
fermentation facility. It was acquired from DSM, a Dutch MNC, and
commenced operations from 2000 with the manufacturing of Penicillin-G
Amidase immobilized enzyme using its polymer matrix. In 2005, Matrix
Laboratories Limited announced its decision to acquire controlling
stake in Concord Biotech. As per the term sheet executed, Matrix would
acquire 55 percent stake in Concord Biotech.
Concord Biotech has a US FDA approved biotechnology facility with
a client base that spreads across the globe including EU,US,
Latin America, Korea, China, Middle East and many other parts of the
world. Concord Biotech has a dedicated biotech and chemical synthesis
R&D for development of biotechnology and down stream
processing. Concord has built up eight dedicated biotech blocks for
manufacturing statins, immunosuppressants, antibiotics and enzymes.
Acquired by Sudhir Vaid, a biotechnologist with 29 years
experience, from DSM.
Concord has diversified in the field of active pharmaceutical
ingredients namely Lovastatin, Pravastatin, Simvastatin and Tacrolimus
and has provided number of technologies on biotech products to many
companies in Europe and India. Concord has received US FDA approval for
its Lovastafin facilities and is striving to go for European Drug
Master Files (EDMF). Concord Biotech offers fermentation services that
rely on more than 30 years of experienced staff.
The company has the capacity and flexibility to ferment and develop
processes for a variety of microbial organisms. Concord is the largest
producer of Penicillin-G Amidase enzyme and is exporting this enzyme to
a number of companies in China, Europe and the US besides having 90
percent market share in India. CBL is also producing and exporting
Lovastatin and Tacrolimus to Europe and other countries. It is also
starting the production of Simvastatin and Pravastatin in its newly US
FDA approved facility in Gujarat. The company has put up a
state-of-the-art manufacturing facility, which is located at Ahmedabad,
Gujarat, and is spread over about 28-acre of land for the
production of hypolipemic agent Lovastatin, Pravastatin and
Simvastatin. It has a dedicated facility for the production of
Tacrolimus, an immunosuppressant.
This apart, CBL has a well-equipped facility not only for the
fermentation but also for the recovery and the powder processing areas.
Concord has the largest shake flask capacity in India, where the wild
strains can be manipulated by conventional mutation programs by a team
of trained scientists. Concord undertakes the custom synthesis projects
in biotechnology area too.